{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:18:38Z","timestamp":1783549118385,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Resistant hypertension in chronic kidney disease (CKD) remains a high-risk clinical phenotype associated with poor blood pressure (BP) control, accelerated kidney disease progression, and excess cardiovascular burden. Aprocitentan, a dual endothelin receptor antagonist approved as add-on therapy for hypertension, offers a new option for patients with resistant hypertension, but its incorporation into CKD care remains constrained by persistent concerns regarding fluid retention. This review synthesizes data from the phase 3 PRECISION program and related endothelin literature to examine how BP lowering, albuminuria reduction, and early volume-related adverse effects should be interpreted in patients with resistant hypertension and CKD. Available evidence suggests that aprocitentan provides clinically meaningful and sustained antihypertensive effects while also producing marked reductions in albuminuria in CKD-enriched high-risk phenotypes, with signals supporting at least partial dissociation between antiproteinuric benefit and systemic BP lowering. The major trade-off is a predictable, front-loaded volume signal characterized by early edema, weight gain, and hemodilution, which appears most relevant during the first weeks after treatment initiation and may be manageable with proactive sodium and diuretic strategies. We also discuss the physiological rationale for combining endothelin blockade with SGLT2 inhibitors as a potential strategy to improve the balance between efficacy and tolerability. Overall, aprocitentan should be interpreted within a clinical benefit-risk framework in which resistant hypertension is the primary therapeutic target, while albuminuria reduction and early volume surveillance define its potential role in CKD.<\/jats:p>","DOI":"10.1038\/s41371-026-01163-4","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:37:02Z","timestamp":1780411022000},"page":"509-514","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aprocitentan in resistant hypertension with chronic kidney disease: balancing albuminuria reduction against early volume risk"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7247-4950","authenticated-orcid":false,"given":"Lucas Maciel de Almeida","family":"Corr\u00eaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6051-1808","authenticated-orcid":false,"given":"Yan Roberth Delmiro","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Costa","family":"de Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1163_CR1","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72:e53\u2013e90. https:\/\/doi.org\/10.1161\/HYP.0000000000000084","journal-title":"Hypertension"},{"key":"1163_CR2","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2215\/CJN.00550113","volume":"8","author":"RM Tanner","year":"2013","unstructured":"Tanner RM, Calhoun DA, Bell EK, Bowling CB, Guti\u00e9rrez OM, Irvin MR, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8:1583\u201390. https:\/\/doi.org\/10.2215\/CJN.00550113","journal-title":"Clin J Am Soc Nephrol"},{"key":"1163_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/MNH.0000000000001002","volume":"33","author":"S Bansal","year":"2024","unstructured":"Bansal S. Revisiting resistant hypertension in kidney disease. Curr Opin Nephrol Hypertens. 2024;33:465\u201373. https:\/\/doi.org\/10.1097\/MNH.0000000000001002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1163_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2023.103788","volume":"28","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang X, Xu S. Aprocitentan, a dual endothelin-1 (ET-1) antagonist for treating resistant hypertension: mechanism of action and therapeutic potential. Drug Discov Today. 2023;28:103788. https:\/\/doi.org\/10.1016\/j.drudis.2023.103788","journal-title":"Drug Discov Today"},{"key":"1163_CR5","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.semnephrol.2015.02.005","volume":"35","author":"M Barton","year":"2015","unstructured":"Barton M, Sorokin A. Endothelin and the glomerulus in chronic kidney disease. Semin Nephrol. 2015;35:156\u201367. https:\/\/doi.org\/10.1016\/j.semnephrol.2015.02.005","journal-title":"Semin Nephrol"},{"key":"1163_CR6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1124\/jpet.118.253864","volume":"368","author":"F Trensz","year":"2019","unstructured":"Trensz F, Bortolamiol C, Kramberg M, Wanner D, Hadana H, Rey M, et al. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther. 2019;368:462\u201373. https:\/\/doi.org\/10.1124\/jpet.118.253864","journal-title":"J Pharmacol Exp Ther"},{"key":"1163_CR7","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","volume":"75","author":"P Verweij","year":"2020","unstructured":"Verweij P, Danaietash P, Flamion B, M\u00e9nard J, Bellet M. Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension. 2020;75:956\u201365. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14504","journal-title":"Hypertension"},{"key":"1163_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s40265-024-02053-0","volume":"84","author":"S Dhillon","year":"2024","unstructured":"Dhillon S. Aprocitentan: first approval. Drugs. 2024;84:841\u20137. https:\/\/doi.org\/10.1007\/s40265-024-02053-0","journal-title":"Drugs"},{"key":"1163_CR9","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400:1927\u201337. https:\/\/doi.org\/10.1016\/S0140-6736(22)02034-7","journal-title":"Lancet"},{"key":"1163_CR10","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","volume":"393","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393:1937\u201347. https:\/\/doi.org\/10.1016\/S0140-6736(19)30772-X","journal-title":"Lancet"},{"key":"1163_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","volume":"21","author":"JFE Mann","year":"2010","unstructured":"Mann JFE, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol. 2010;21:527\u201335. https:\/\/doi.org\/10.1681\/ASN.2009060593","journal-title":"J Am Soc Nephrol"},{"key":"1163_CR12","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","volume":"402","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, et al. Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial. Lancet. 2023;402:2004\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(23)02230-4","journal-title":"Lancet"},{"key":"1163_CR13","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","volume":"7","author":"HJL Heerspink","year":"2019","unstructured":"Heerspink HJL, Greene T, Tighiouart H, Gansevoort RT, Coresh J, Simon AL, et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol. 2019;7:128\u201339. https:\/\/doi.org\/10.1016\/S2213-8587(18)30314-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1163_CR14","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.25563","volume":"83","author":"P Rossignol","year":"2026","unstructured":"Rossignol P, Clozel M, Dreier RF, Flack JM, Flamion B, Mann J, et al. Aprocitentan in patients with chronic kidney disease and resistant hypertension. Hypertension. 2026;83:e25563 https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.125.25563","journal-title":"Hypertension"},{"key":"1163_CR15","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1002\/cpt.2043","volume":"109","author":"P Gueneau de Mussy","year":"2021","unstructured":"Gueneau de Mussy P, Sidharta PN, Wuerzner G, Maillard MP, Gu\u00e9rard N, Iglarz M, et al. Effects of the dual endothelin receptor antagonist aprocitentan on body weight and fluid homeostasis in healthy subjects on a high sodium diet. Clin Pharmacol Ther. 2021;109:746\u201353. https:\/\/doi.org\/10.1002\/cpt.2043","journal-title":"Clin Pharmacol Ther"},{"key":"1163_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159\u201364. https:\/\/doi.org\/10.1001\/archinte.168.11.1159","journal-title":"Arch Intern Med"},{"key":"1163_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/ajh\/hpae092","volume":"37","author":"V Vallon","year":"2024","unstructured":"Vallon V. State-of-the-art-review: mechanisms of action of SGLT2 inhibitors and clinical implications. Am J Hypertens. 2024;37:841\u201352. https:\/\/doi.org\/10.1093\/ajh\/hpae092","journal-title":"Am J Hypertens"},{"key":"1163_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816","journal-title":"N Engl J Med"},{"key":"1163_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233","journal-title":"N Engl J Med"},{"key":"1163_CR20","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.0000000000000436","volume":"35","author":"JD Smeijer","year":"2024","unstructured":"Smeijer JD, Wasehuus VS, Dhaun N, G\u00f3rriz JL, Soler MJ, \u00c5strand M, et al. Effects of zibotentan alone and in combination with dapagliflozin on fluid retention in patients with CKD. J Am Soc Nephrol. 2024;35:1381\u201390. https:\/\/doi.org\/10.1681\/ASN.0000000000000436","journal-title":"J Am Soc Nephrol"},{"key":"1163_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/HYPERTENSIONAHA.124.24142","volume":"82","author":"JM Flack","year":"2025","unstructured":"Flack JM, Schlaich MP, Weber MA, Sassi-Sayadi M, Narkiewicz K, Clozel M, et al. Aprocitentan for blood pressure reduction in Black patients. Hypertension. 2025;82:601\u201310. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.124.24142","journal-title":"Hypertension"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01163-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01163-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:02:27Z","timestamp":1783548147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-026-01163-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":21,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1163"],"URL":"https:\/\/doi.org\/10.1038\/s41371-026-01163-4","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article is a narrative review of previously published literature and did not involve new studies with human participants or animals performed by any of the authors. Ethical approval was therefore not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}